The World Market for Infectious Disease Diagnostic Tests

    Published: October 21, 2013 | Price: $3,995.00 – $7,990.00

    Infectious diseases are among the most challenging issues facing health care delivery systems around the world today. The World Health Organisation estimates that more than 17 million people die of an infectious disease each year, with many of these acquired in hospitals. This Kalorama Information report, The World Market for Infectious Disease Diagnostic Tests, takes a comprehensive look at the markets for companies of testing products that can combat infectious disease threats. One of the Most Dynamic Areas of the...
    The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)

    Published: October 16, 2013 | Price: $3,995.00 – $7,990.00

    The effectiveness of biomarkers has made them essential to medicine, with successful products on the market and many products in development.   This Kalorama Information report focuses on both the clinical biomarkers and research biomarkers in medicine. Biomarkers are physiologic, genetic or biochemical parameters that provide insight into understanding disease processes and ways that medicines can work to counteract the disease.  With them, diseases are detected earlier, more effective treatments can be delivered, drug reactions reduced.  An example is creatine kinase,...
    The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

    Published: September 22, 2013 | Price: $2,995.00 – $6,000.00

    The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment....
    Laboratory Information Systems (LIS / LIMS): Software, Hardware and Service Markets for Clinical Labs and Drug Discovery Labs

    Published: September 19, 2013 | Price: $2,500.00 – $5,000.00

    Laboratory Information Systems (LIS / LIMS) Markets (Clinical Laboratory Software and Hardware, Drug Discovery Systems) Laboratory information systems (LIS), also known as laboratory information management systems (LIMS), are data and information management systems designed for industrial and medical-related laboratories, including clinical and analytical laboratories. This Kalorama Information market report, The World Market for Lab Information Systems (LIS) analyzes the current and potential world markets for medical laboratory information system software and hardware -- both for the clinical diagnostics lab and...
    The IVD Market in Brazil

    Published: September 13, 2013 | Price: $1,500.00 – $3,000.00

    Brazil is the fifth largest country in the world, after Russia, Canada, China and the United States. The size of the country as made it a focus for IVD companies. This report, The IVD Market in Brazil, provides market estimates and forecasts for the main categories of in vitro diagnostics, and forecasts those markets to 2017. Information was obtained by both primary and secondary sources. Annual reports, trade publications, as well as telephone and email surveys of IVD manufacturers operating...
    Medical Device Tax: Will There Be a R&D Effect?

    Published: September 13, 2013 | Price: $50.00 – $100.00

    The medical device tax that took effect Jan. 1, 2013 for all manufacturers of Class I, Class II and Class III devices in the United States may have had an impact on device company spending, according to this complimentary Public Policy Paper from Kalorama Information.  While the tax was in effect in the 2012 year, the paper looks at budgeted R&D spending as companies anticipated new costs from the program. The conclusions are the result of information from Kalorama Information's...
    The World Market for Cloud Computing in Healthcare (Saas, IaaS, PaaS, Other Cloud Markets, Healthcare IT Spending and Other Trends)

    Published: September 10, 2013 | Price: $995.00 – $1,990.00

    The World Market for Cloud Computing in Healthcare Healthcare providers around the world are facing rising costs while they attempt to maintain or improve care. Healthcare information technology (HIT) is a key component of streamlining healthcare in a way that can provide benefits to those involved. As this report details, cloud computing is a way of using existing technology to modernize the healthcare industry. Cloud technologies are generally off-site, third-party-managed computing resources that can include computational resources, additional data storage...
    The World Market for Minimally Invasive Surgical Devices (Cardiovascular, ENT, Neurosurgery, Gastrointestinal, Urological/Gynecological and Other MIS Device Markets)

    Published: August 21, 2013 | Price: $2,500.00 – $5,000.00

    This report, The World Market for Minimally Invasive Surgical Devices, includes product information, procedure volume data, world demographics, and other general issues affecting the MIS device market.   Minimally invasive surgery (MIS) currently allows doctors to perform many complicated operations with a short hospital stay, better patient satisfaction and outcomes.  The concept has driven the growth of devices for minimally invasive procedures. In this report, a detailed market analysis includes  six general surgery areas reflecting revenues earned by all manufacturers in...
    The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry

    Published: August 16, 2013 | Price: $995.00 – $1,995.00

    The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry The "Patient Protection and Affordable Care Act" (H.R. 3590) is complex legislation that affects virtually every aspect of health care, and many of its provisions are beginning to take effect now.  IVD manufacturers who have different needs and strategies are now considering the legislation and whether it will help or hurt business plans. The legislation contains a range of different provisions and while the law in a broad sense...
    The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)

    Published: August 15, 2013 | Price: $3,995.00 – $7,990.00

    The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Circulating tumor cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new tumors. These cells that leave the primary tumor are able to colonize distant organs in the body and initiate the process of metastasis; however, their biology is still not entirely elucidated. Circulating tumor cells have tremendous utility in cancer research, aiding scientists in deciphering...
    The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)

    Published: August 9, 2013 | Price: $3,995.00 – $7,990.00

    This  Kalorama Information report  The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment) focuses on the market for preventing, testing and treating infections in the healthcare environment. Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI.  ...
    IVD in China

    Published: August 5, 2013 | Price: $2,500.00 – $5,000.00

    This report, IVD in China represents Kalorama's complete analysis on the Chinese IVD market.  The report provides an introduction to the healthcare system in China, the results of recent reform efforts, and issues and trends.  Regional breakouts of the Chinese system are provided.  The report describes the role that out-of-pocket expenditures and private concerns play in the delivery of healthcare in the nation. The modern Chinese healthcare market was borne of and continues to be guided by the progressive intentions...
    IVD in Australia

    Published: August 5, 2013 | Price: $1,995.00 – $3,990.00

    Australia represents a highly competitive IVD market with established international players, a highly developed export-intensive domestic industry, and highly consolidated clinical lab and testing industry. While other developed IVD markets in North America, Europe and Japan are not estimated to be achieving above 3% annual growth, the Australian IVD market has grown at an average of roughly 5% through the past five years. This rate of growth is projected to more or less continue with a stable funding environment through...
    Lateral Flow Technology And The Future Of Point Of Care Diagnostics, 2nd Edition

    Published: August 1, 2013 | Price: $4,200.00 – $8,400.00

    Lateral flow tests, also known as immunochromatographic strip (ICS) tests, are point of care tests that reduce the time spent waiting for test results from hours to minutes, require less training for operators, and reduce the cost of both device development and care. This report, Lateral Flow Technology and the Future of Point of Care Testing, 2nd Edition, takes an in depth look at the market, technologies, and trends in lateral flow point-of-care testing, looking at both self-testing by patients...
    Next Generation Sequencing Trends (Clinical Applications, Systems Used, Accreditation Status, Regulated Patient Sample Handling and Other Trends)

    Published: July 1, 2013 | Price: $1,500.00 – $3,000.00

    Next Generation Sequencing Trends (Clinical Applications, Systems Used, Accreditation Status, Regulated Patient Sample Handling and Other Trends) Next-generation sequencing is discussed frequently as a key to clinical diagnostics in the future. This report looks at the status of NGS today, and seeks to provide insights on the “on-the-ground” status of clinical sequencing. In the course of doing this, the report seeks to answer the following questions: What is the status of clinical applications for Next Gen in laboratories currently? What...